Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-06

Study Completion Date

2027-03-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Normalizing weight gain and preventing the redistribution of body fat is a major health issue, and could help prevent the onset of various symptoms of metabolic syndrome. Above all, it is important to understand the mechanisms by which these different treatments affect adipose tissue. To this end, the investigators will first study the impact of GLP-1 analogues on adipose tissue. The main objective is to show that subjects treated with a GLP-1 agonist have a significant change in their oxytocin levels compared with subjects not treated with a GLP-1 agonist.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bariatric Surgery Combined With GLP-1 Receptor Agonists Study

NCT07336862

Obesity

RECRUITING PHASE1/PHASE2

Impact GLP-1 Agonists Following Bariatric

NCT06132477

Morbid Obesity Metabolic Syndrome Diabetes Mellitus +2 more

RECRUITING PHASE4

Metabolomics and Bariatric Surgery in Patients With Metabolically Unhealthy Obesity

NCT06297928

Bariatric Surgery Candidate Obesity, Morbid Obesity, Metabolically Benign

COMPLETED

Relationship Between Changes in Gut Hormones After Gastric Bypass and Gastric Banding and Improvements in Diabetes

NCT01153438

Type 2 Diabetes Obesity Bariatric Surgery

COMPLETED

Effect of Bariatric Surgery on Brain Insulin Sensitivity

NCT03705923

Obesity

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

whole blood in a GLP1

Oxytocyne assay in a GLP1 analogue or non-analogue patient population

Group Type OTHER

Blood GLP1

Intervention Type OTHER

On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with anti-GLP-1 analogues

whole blood in non analague patient population

Oxytocyne assay in a GLP1 analogue or non-analogue patient population

Group Type OTHER

Blood No treated GLP1

Intervention Type OTHER

On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with patients not treated with anti-GLP-1 analogues) and the presence of fibrosis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood GLP1

On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with anti-GLP-1 analogues

Intervention Type OTHER

Blood No treated GLP1

On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with patients not treated with anti-GLP-1 analogues) and the presence of fibrosis.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient over 18 years of age.
* Patient able to read and understand the information/consent leaflet.
* Patient with BMI \> 35 with at least one comorbidity. Or BMI \> 40
* Indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the CPAM.
* Membership of a social security scheme
* Patient's signed informed consent
* For subjects in the GLP-1 analogue group: GLP-1 analogue taken for at least 3 months.
* For non-GLP-1 analogue group: never taken GLP-1 analogues.